Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

Ipsogen Accesses Affymetrix Microchip Technology for Development of IVD Tests

  • Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.

    The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will, the companies report, enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »